Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis.

Front Pharmacol · 2025 · PMC12832817 · PMID 41601958

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0500

boldest claim

The sentences

highly significantP < 0.0001actually significant

(2024) ( Paz-Ares et al., 2024 ), the OR increased to 2.67, a change that was highly significant ( P < 0.0001).

also in 132,142 other papers

did not reach statistical significanceP > 0.05actually significant

In the ungrouped analysis, the overall risk of grade 3 or higher AE did not reach statistical significance ( P > 0.05), and substantial heterogeneity was observed ( Figure 7B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.